News round-up for 28 Oct – 1 Nov by DDW Senior Digital Content Editor Diana Spencer.

In a week that saw a second monoclonal antibody rejected by UK regulator NICE, antibodies have been high on the news agenda. More positively, a new indication for Fasenra was approved in the EU, researchers found an antibody platform could overcome the challenges of treating mutating viruses, and monoclonal antibodies showed promise in lung cancer and immunoglobulin A nephropathy.

The top stories:

UK’s NICE rejects second disease-modifying therapy for Alzheimer’s

UK regulator the National Institute for Health and Care Excellence (NICE) has ruled against the use of a second monoclonal antibody for Alzheimer’s disease, just two months after rejecting Eisai’s lecanemab (Leqembi).

Antibody platform overcomes mutational escape in Covid-19

Scientists have developed a unique antibody platform to tackle the challenges of treating rapidly evolving viruses like SARS-CoV-2 due to their ability to mutate and evade therapies.

EU approves new indication for AstraZeneca’s Fasenra

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Trial assesses new approach to NSCLC with MET alterations

The first patient has been dosed with PFL-002/VERT-002 in a Phase I/II first-in-human trial for patients with non-small cell lung cancer (NSCLC) with MET alterations.

Positive news for IgAN treatment presented at Kidney Week

Positive data from two trials in immunoglobulin A nephropathy (IgAN) were shared at the American Society of Nephrology Kidney Week 2024 in San Diego, California.